UK: Patchy Report From A Gynaecology Conference Is Enough To Put A Bullet In Richter Gedeon’s Morning After Pill Patent

Last Updated: 11 July 2014
Article by Richard Newell and Mark Ness

The UK's High Court has decided that Richter Gedeon's patent for a single dose of the emergency contraceptive levonorgestrel is invalid in view of a report published a few months before the priority date revealing the preliminary results from an incomplete study of the drug.


Levonorgestrel is the active ingredient in the most commonly employed hormone-based emergency contraceptive. The drug is a synthetic version of the natural hormone progesterone.

Levonorgestrel is currently marketed in the UK by Bayer as Levonelle One Step®. Levonelle One Step® is a tablet containing 1.5 mg of levonorgestrel that is 84% effective as an emergency contraceptive when taken as a single dose 12–72 hours after unprotected intercourse.

Richter Gedeon's patent EP (UK) 1 448 207 had three claims. Claim 1 was directed to a pharmaceutical composition of 1.5 mg levonorgestrel (± 0.2 mg), for use as a single dose. Claim 2 was a claim directed to the same dose of levonorgestrel for use in emergency contraception (in 'Swiss' form in order to comply with EPO law against medical treatment claims), and dependent claim 3 limited that dosage regimen of claim 2 to a single application, administered within 72 hours of unprotected intercourse.

The European patent was granted in 2005 and not opposed centrally at the EPO. In order to kill the EP (UK) patent, Mylan launched an action in the UK High Court seeking revocation. The case dealt only with validity. There was no claim for infringement from Richter Gedeon.

Arguments and judgment

Mylan attacked the patent on two grounds. The primary attack was obviousness, and the secondary attack was insufficiency (non-enabling disclosure). The insufficiency attack was an attempted 'squeeze' argument in case the obviousness attack failed, but since the obviousness attack succeeded, the judgment does not deal with the second attack in detail.

Levonorgestrel was known in the art as an emergency contraceptive. However, the drug was taken in two doses of 0.75 mg, 12 hours apart. The invention in the patent was taking 1.5 mg as one dose. The attack of obviousness concerned a single piece of prior art. This was a report in a special edition of the journal Gynaecology Forum, reporting the highlights of a world congress on gynaecology and obstetrics in Washington DC. The article included a short report of a presentation of the initial results of a medical study comparing the effectiveness of a single dose of 1.5 mg levonorgestrel against two other methods of emergency contraception: (i) two-dose treatment with levonorgestrel; and (ii) another contraceptive. Richter Gedeon had supported the study by providing levonorgestrel.

The subject of the report was noticeably close to the claims, but suffered from three deficiencies:

  1. The three contraceptive methods compared in the study were simply named A, B, and C. The single dose of 1.5 mg levonorgestrel was not identified, presumably because the study was double-blind.
  2. The report consistently stated that the dose of levonorgestrel was 1.5 g (not mg).
  3. The report clearly stated that the study was incomplete, so the results could not be relied on. For example, the report stated:
  • "This study is still in progress but an interim comparison between the groups was presented by Dr von Hertzen."
  • "Dr Glasier advised great caution with [the assumption that a single dose of 1.5 g levonorgestrel was the preferred oral method] as the trial was still incomplete. The last few subjects could alter the data and it was wrong to try to guess which group was which, however tempting this might be."

As regards the unbroken code (formulations A, B and C), the court held that the report still showed that a single dose of levonorgestrel was effective, because the report said that all formulations had similar effectiveness.

As regards the erroneous dose of 1.5 g in the report, Mylan were not able to persuade the court that this would automatically have been read as 1.5 mg. However, Mylan successfully argued that the skilled person would have immediately identified the error and found the real dose elsewhere.

As regards the incomplete nature of the preliminary results, and the consequent caveats at the end of the report, Richter Gedeon attempted to argue that obviousness should be assessed from the view of a medical statistician, who would not have considered the single dose to be effective from these incomplete data. However, the court rejected this argument and held that obviousness should more accurately be assessed from the view of a medical practitioner rather than a statistician. The court held that a practitioner would have considered the one-dose regimen to be a viable form of emergency contraception in view of the report, and that there was then nothing inventive about completing the study. The court held that the invention had been "substantively revealed" as an "obvious likely way forward" by the report.


The claims related to a specific dosage regimen (a single dose of 1.5 mg), for a specific medical use (emergency contraception). Notably, the court considered the claim to require the dosage regimen to be "reasonably effective" in the medical application. Inventive step then hinged on whether this effectiveness had been revealed in the prior art, with a reasonable expectation of success. Although the preliminary results in the prior art were not watertight, the court found that the conference disclosure had made the regimen seem viably useful, and the patent was revoked for lacking inventive step.

Need advice?

Carpmaels & Ransford LLP is a leading firm of European patent and trade mark attorneys based in London. For more information about our firm and our practice, please visit our website at

This Briefing Note was first published in the IAM IP Newsletter.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.